TRAVERE THERAPEUTICS INC
NASDAQ: TVTX (Travere Therapeutics, Inc.)
Last update: 2 hours ago58.85
-0.18 (-0.30%)
| Previous Close | 59.03 |
| Open | 59.34 |
| Volume | 4,126,165 |
| Avg. Volume (3M) | 2,543,666 |
| Market Cap | 5,472,632,320 |
| Price / Earnings (Forward) | 80.65 |
| Price / Sales | 9.89 |
| Price / Book | 55.43 |
| 52 Weeks Range |
| Profit Margin | -82.88% |
| Operating Margin (TTM) | -52.21% |
| Diluted EPS (TTM) | -2.78 |
| Quarterly Revenue Growth (YOY) | 97.50% |
| Total Debt/Equity (MRQ) | 1,220.07% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | -160.66 M |
| Levered Free Cash Flow (TTM) | -239.23 M |
| Return on Assets (TTM) | -23.21% |
| Return on Equity (TTM) | -422.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Travere Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 113.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Janus Henderson Group Plc | 31 Mar 2026 | 11,419,586 |
| Armistice Capital, Llc | 31 Mar 2026 | 4,897,417 |
| Perceptive Advisors Llc | 31 Mar 2026 | 4,142,551 |
| Nomura Investment Management Business Trust | 31 Mar 2026 | 3,270,513 |
| Stephens Investment Management Group Llc | 31 Mar 2026 | 1,798,466 |
| Kynam Capital Management, Lp | 31 Mar 2026 | 1,569,018 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |